EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gene-Specific Outcomes After Central Nervous System Metastases in Germline BRCA1- and BRCA2-Associated Breast Cancer

Alice Decaminada iD, Raute Sunder-Plassmann iD, Weang-Kee Ho iD, Daniela Muhr, Angelika M Starzer iD, Anna Sophie Berghoff, Rupert Bartsch, Christian F Singer iD, kConFab Investigators, Yen Y Tan iD

Cancers · 14.04.2026 · 18 (8) · 1240

DOI: 10.3390/cancers18081240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 14.04.2026. Verfasst von Alice Decaminada und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna, Pfizer, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Many studies evaluating central nervous system (CNS) metastases in breast cancer (BC) combine germline BRCA1 and BRCA2 pathogenic variant carriers, limiting gene-specific interpretation. We evaluated gene-specific overall survival (OS) after CNS metastasis and time to CNS involvement.

Methods

We retrospectively identified BC patients with confirmed CNS metastases (1995–2022) from the Medical University of Vienna and the kConFab consortium. Germline status was classified as gBRCA1 PV, gBRCA2 PV, or non-carrier. Primary endpoint was OS from CNS metastasis diagnosis; secondary endpoint was CNS metastasis-free interval from primary BC diagnosis. Kaplan–Meier/log-rank tests were used for group comparisons. Multivariable Cox models assessed OS in complete cases, stratified by molecular subtype and adjusted for prognostic factors. Sensitivity analyses included subtype-adjusted and time-period models.

Results

Among 115 patients (gBRCA1 n = 32, gBRCA2 n = 18, and non-carriers n = 65), median OS differed by germline status (p = 0.019): 20.0 months (95% CI 6.7–60.0) for gBRCA2 versus 7.1 months (95% CI 3.7–10.0) for gBRCA1 and 7.6 months (95% CI 3.4–12.0) for non-carriers. In subtype-stratified analyses, gBRCA1 showed similar mortality to non-carriers (HR 0.90, 95% CI 0.49–1.64, p = 0.730), while gBRCA2 showed a lower but non-significant hazard (HR 0.48, 95% CI 0.18–1.25, p = 0.131). Median CNS metastasis-free interval was longer for gBRCA2 (8.4 years) versus gBRCA1 (3.0 years) and non-carriers (3.1 years; p = 0.020). Sensitivity analyses were consistent. Conclusions: gBRCA2 carriers demonstrated longer unadjusted OS after CNS metastasis and a longer CNS metastasis-free interval compared with gBRCA1 carriers and non-carriers. However, these associations were attenuated and not statistically significant after adjustment, and should therefore be interpreted as hypothesis-generating. These findings supports further investigation of gene-specific CNS disease trajectories in larger cohorts.

Schlagwörter

Stichwörter der Autor:innen

BRCA1BRCA2CNS metastasisbrain metastasisbreast canceroverall survival

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
  • Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
  • Faculty of Medical and Life Sciences, Sunway University, Petaling Jaya 47500, Selangor, Malaysia.
  • Cancer Research Malaysia, Subang Jaya 47500, Selangor, Malaysia.
  • Department of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria.
  • The Peter MacCallum Cancer Centre, Melbourne, VIC 3010, Australia.

ORCID-Profile: Alice Decaminada, Raute Sunder-Plassmann, Weang-Kee Ho, Angelika M Starzer, Christian F Singer, Yen Y Tan

Förderung

  • Medical University of Vienna
  • Pfizer
  • AstraZeneca

Zitieren

APA

Decaminada, A., Sunder-Plassmann, R., Ho, W. K., Muhr, D., Starzer, A. M., Berghoff, A. S., Bartsch, R., Singer, C. F., kConFab Investigators, & Tan, Y. Y. (2026). Gene-Specific Outcomes After Central Nervous System Metastases in Germline BRCA1- and BRCA2-Associated Breast Cancer. Cancers, 18(8), 1240. https://doi.org/10.3390/cancers18081240

Vancouver

Decaminada A, Sunder-Plassmann R, Ho WK, Muhr D, Starzer AM, Berghoff AS, et al. Gene-Specific Outcomes After Central Nervous System Metastases in Germline BRCA1- and BRCA2-Associated Breast Cancer. Cancers. 2026;18(8):1240. doi:10.3390/cancers18081240

BibTeX
@article{Decaminada2026,
  author = {Decaminada, Alice and Sunder-Plassmann, Raute and Ho, Weang-Kee and Muhr, Daniela and Starzer, Angelika M and Berghoff, Anna Sophie and Bartsch, Rupert and Singer, Christian F and kConFab Investigators and Tan, Yen Y},
  title = {Gene-Specific Outcomes After Central Nervous System Metastases in Germline BRCA1- and BRCA2-Associated Breast Cancer},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {1240},
  doi = {10.3390/cancers18081240}
}
Kostenlos starten →